NCT02639910: A trial that was reported late by MorphoSys AG
This trial has reported, although it was 13 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02639910 |
|---|---|
| Title | A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 30, 2016 |
| Completion date | Nov. 30, 2018 |
| Required reporting date | Nov. 30, 2019, midnight |
| Actual reporting date | Dec. 13, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 13 |